CANY
CDLX icon

Caxton Associates (New York)’s Cardlytics CDLX Stock Holding History

Caxton Associates (New York)’s Portfolio CDLX Stock Details CDLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-857
Closed -$300K – 472
2020
Q1 		$300K Buy
857
+315
+58% +$223K 0.06% 261
2019
Q4 		$340K Buy
+542
New +$265K 0.05% 249

Other funds holding CDLX

CIP
CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KGAMU
KPS Global Asset Management (UK) London, United Kingdom $620M AUM 14.15% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
AA
Antipodean Advisors New York $19.5M AUM 6.21% 1-Year Est. Return

Caxton Associates (New York)'s CDLX Position: Q2 2020 in Review

Caxton Associates (New York) sold out of Cardlytics (CDLX) in Q2 2020, closing a stake of 857 shares — an estimated $300K sold.

Caxton Associates (New York) first reported a position in CDLX in Q4 2019 and held it in 2 quarters. The position peaked at $340K in Q4 2019. 164 funds tracked by Wall St. Rank hold CDLX as of Q2 2020.

  • Caxton Associates (New York) reported no remaining Cardlytics position as of Q2 2020 after selling out during the quarter.
  • Caxton Associates (New York) sold 857 Cardlytics shares in Q2 2020, an estimated $300K.
  • Caxton Associates (New York) first reported a position in Cardlytics in Q4 2019 and held it in 2 quarters.
  • Caxton Associates (New York)'s Cardlytics position peaked at $340K in Q4 2019.
  • 164 funds tracked by Wall St. Rank held Cardlytics as of Q2 2020.

Based on Caxton Associates (New York)'s 13F filing for Q2 2020, filed 14 Aug 2020.